### 1 Enhanced hemato-endothelial specification during human embryonic differentiation

- through developmental cooperation between AF4-MLL and MLL-AF4 fusions 2 3 Clara Bueno<sup>1,6\*</sup>, Fernando J Calero-Nieto<sup>2</sup>, Xiaonan Wang<sup>2</sup>, Rafael Valdés-Mas<sup>3</sup>, 5 Francisco Gutiérrez-Agüera<sup>1</sup>, Heleia Roca-Ho<sup>1</sup>, Veronica Ayllon<sup>4</sup>, Pedro J Real<sup>4</sup>, David Arambilet<sup>5</sup>, Lluis Espinosa<sup>5,6</sup>, Raul Torres-Ruiz<sup>1</sup>, Antonio Agraz-Doblas<sup>1,7</sup>, Ignacio Varela<sup>7</sup>, Jasper de Boer<sup>8</sup>, Anna Bigas<sup>5,6</sup>, Bertie Gottgens<sup>2</sup>, Rolf Marschalek<sup>9</sup>, Pablo Menendez<sup>1,6,10\*</sup>
- 9

4

6

7

8

<sup>1</sup>Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine. 10 University of Barcelona. Barcelona. Spain. <sup>2</sup>Department of Hematology, Cambridge Institute for Medical 11 Research and Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, University of 12 Cambridge, United Kingdom. 3Dreamgenics S.L. Oviedo. Spain. 4GENyO, Centre for Genomics and 13 Oncological Research, Pfizer/University of Granada/Andalusian Regional Government and University of 14 15 Granada, Department of Biochemistry and Molecular Biology, Granada, Spain. <sup>5</sup>Programa de Cáncer. Instituto Hospital del Mar de Investigaciones Médicas. Barcelona. Spain. 6Centro de Investigación Biomédica 16 en Red de Cáncer (CIBER-ONC), ISCIII, Barcelona, Spain. 7Instituto de Biomedicina y Biotecnología de 17 Cantabria (CSIC-UC-Sodercan), Departamento de Biología Molecular, Universidad de Cantabria, Santander, 18 Spain. 8Cancer Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom. 19 20 <sup>9</sup>Institute of Pharmaceutical Biology, Goethe-University. Frankfurt. Germany. <sup>10</sup>Instituciò Catalana de Recerca i Estudis Avançats (ICREA). Barcelona. Spain. 21

- 22
- Running Title: AF4-MLL in human embryonic hematopoietic development 23
- 24 Key words: AF4-MLL, MLL-AF4, HOX cluster, human ESC, hemato-endothelial specification.
- 25
- 26
- 27

#### 28 \*Correspondence should be addressed to:

- 29 Clara Bueno PhD & Pablo Menendez PhD
- 30 Josep Carreras Leukemia Research Institute
- School of Medicine. University of Barcelona. 31
- Casanova 143, 08036. Barcelona. Spain. 32
- 33 cbueno@carrerasresearch.org; pmenendez@carrerasresearch.org
- 34
- 35
- 36
- 37
- 38

### 39 ABSTRACT

40 The t(4;11)(g21;g23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia 41 and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of 42 the t(4:11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed 43 in t(4;11)+ B-cell acute lymphoblastic leukemia patients, but the reciprocal fusion A4M is expressed in only 44 half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic 45 differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic 46 differentiation models to study whether the A4M fusion cooperates with MA4 during early human 47 hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-48 endothelial precursors, both endothelial- and hemogenic-primed. Double fusion-expressing hemato-49 endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-50 committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. 51 Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions 52 by RNA-seq and H3K79me3 ChIP-seq, respectively, confirmed a hematopoietic/endothelial cell 53 differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, ChIP-seq 54 analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A 55 cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish 56 a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic 57 development.

- 58
- 59
- 60
- 61
- 62

### 63 INTRODUCTION

64 The mixed-lineage leukemia (MLL) gene encodes for an H3K4 histone methyltransferase important in 65 hematopoietic development<sup>1</sup>. The human *MLL* gene is frequently rearranged in acute leukemia and typically 66 confers a dismal outcome<sup>2,3</sup>. Of particular interest is the translocation t(4:11)(g21:g23), which encodes the fusion proteins MLL-AF4 (MA4) and AF4-MLL (A4M), and is associated with infant B-cell acute lymphoblastic 67 68 leukemia (B-ALL). This t(4:11)+ infant leukemia is characterized by a very brief latency, raising the guestion 69 of how it evolves so guickly<sup>4</sup>. Moreover, the exceptionally high concordance rate of t(4;11)+ B-ALL in 70 monozygotic twin infants<sup>5,6</sup> suggests that all the necessary (epi)genetic events required for leukemogenesis 71 are accomplished prenatally, during embryonic/fetal hematopoietic development<sup>7</sup>. However, our 72 understanding of t(4;11)-mediated developmental effects is limited, at least in part, due to the variety of 73 phenotypes and long latency observed in currently available t(4;11) mouse models<sup>2,8-17</sup>. These different 74 phenotypes likely result from targeting a cell in the wrong developmental stage, or not addressing the impact 75 of secondary hits, leaving open questions about the developmental impact of the t(4:11) translocation during 76 early human development.

77

78 The functional and molecular contribution of the reciprocal fusion genes resulting from the derivative 79 translocated chromosomes remains obscure in cancer. The MA4 fusion is always expressed in t(4;11)+B-80 ALL patients, whereas the reciprocal fusion A4M is expressed in only half of the patients<sup>18-20</sup>. Importantly, 81 t(4;11)+ cell lines display addiction to MA4 but not to A4M<sup>21,22</sup>, and although A4M was not sufficient to initiate 82 leukemia in cord blood-derived CD34+ cells<sup>23</sup>, it was nevertheless capable of initiating B-ALL in mice without 83 the requirement of MA4, indicating that it contributes to t(4;11)-driven leukemogenesis<sup>11,24,25</sup>. Strikingly, a 84 very recent clinical study have unraveled an independent prognostic value for MA4 expression in t(4:11)+ 85 infant B-ALL, thus adding a new piece to the puzzle<sup>19</sup>. Thus, the developmental/pathogenic contribution of 86 the t(4;11)-resulting reciprocal fusion A4M remains enigmatic.

Human embryonic stem cells (hESCs) represent a powerful tool for modeling different developmental aspects of human disease that cannot otherwise be addressed by patient sample analyses or mouse models<sup>7,26,27</sup>. Because prenatal leukemogenesis manifests as impaired early hematopoietic differentiation, modeling hematopoietic differentiation in hESCs may represent a promising in vitro approach to study the onset of hematopoiesis and the mechanisms underlying early human hematopoietic development<sup>7</sup>. During hESC differentiation, a primitive population of CD45- hemato-endothelial precursors (HEPs) arises and further differentiates into CD45+ hematopoietic and mature endothelial cells<sup>28-30</sup>. Beyond their pathogenic role in acute leukemias, the MLL gene has also been implicated in endothelial cell maturation<sup>31</sup>, and endothelial dysfunction was recently linked to disease outcomes in childhood leukemias<sup>32</sup>. We previously reported that MA4 favors the emergence of endothelial-primed HEPs but not hemogenic HEPs from hESCs<sup>10</sup>. Here, we took advantage of well-established hESC-based differentiation systems to study whether the A4M fusion cooperates with MA4 during early human hematopoietic and endothelial development. We report a functional and molecular cooperation between MA4 and A4M fusions, which results in an enhanced hemato-endothelial output during human embryonic development. 

### 111 METHODS

### 112 Vector construction and lentiviral transduction

113 The cDNAs for MA4 and A4M were subcloned into the pRRL-EF1α-PGK-NEO vector<sup>11, 16</sup>. Both fusions have 114 been described previously (**FigS1A**)<sup>11,23</sup>. We used the following lentivectors containing either neomycin or 115 dTo for cell selection: pRRL-EF1a-PGK-NEO (empty vector; EV), pRRL-EF1a-MA4-PGK-NEO (MA4) and 116 pRRL-EF1a-A4M-PGK-dTo (A4M). VSV-G-pseudotyped lentiviral particles were generated in 293T cells using standard transfection protocols and concentrated by ultracentrifugation<sup>33</sup>. hESCs were infected 117 118 overnight with concentrated EV or MA4 lentivirus plus 8 µg/ml polybrene. Viral supernatants were washed 119 away the next day, and EV- and MA4-transduced hESCs were then selected with G418 (50-100µg/ml) for 120 three weeks. For dual transduction of MA4 and A4M fusions, G418-resistant MA4-expressing hESCs were 121 infected with A4M-expressing viruses. EV/G418-selected hESCs were also transduced with A4M alone. 122 Transgene expression was confirmed for all the genotypes (Fig1).

123

### 124 Human ESC culture and characterization of transgenic human ESC lines

125 hESCs (AND1 line) were maintained undifferentiated on a layer of irradiated-hMSCs (iMSC) in complete KO-DMEM medium containing 20% knockout serum replacement and 8 ng/mL basic fibroblast growth factor 126 127 (bFGF)<sup>34, 35</sup>. The medium was changed daily, and cells were passaged weekly by dissociation with 1:1 128 collagenase IV:Dispase. Cultures were visualized daily by phase contrast microscopy. Approval for hESC 129 work was obtained from the Spanish National Embryo Ethical Committee. Pluripotency of transgenic hESCs 130 was characterized by flow cytometry using antibodies against SSEA-3, SSEA-4 TRA-1-60 and TRA-1-81 (BD 131 Biosciences)<sup>36</sup>. Expression of the pluripotency-associated transcription factors OCT4, NANOG, SOX2, 132 CRIPTO, and DNMT3B as well as transgene expression (MA4 and A4M) were analyzed by gRT-PCR. 133 **TableS1** shows the primers and PCR conditions used<sup>23,37,38</sup>.

### 134 Hematopoietic differentiation from human ESCs by embryoid body formation.

135 Undifferentiated hESCs were treated with collagenase IV:Dispase for 1 hr at 37°C. For embryoid body (EB) 136 formation, cells were transferred to low-attachment plates and incubated overnight in differentiation medium 137 (DM; KO-DMEM supplemented with 20% FBS, 1% nonessential amino acids, 1 mmol/L L-glutamine, and 0.1 138 mmol/L  $\beta$ -mercaptoethanol). The medium was changed next day to the same DM supplemented with the 139 following hematopoietic cytokines: 300 ng/mL stem cell factor (SCF), 300 ng/mL Flt3L, 10 ng/mL interleukin 140 (IL)-3, 10 ng/mL IL-6, 50 ng/mL granulocyte-colony stimulating factor (G-CSF) and 25 ng/mL bone 141 morphogenetic protein 4 (BMP-4) (all from R&D)<sup>9,29,39-41</sup>. EBs were dissociated at different time points during 142 development using collagenase B and enzyme-free Cell Dissociation Buffer (Invitrogen). Dissociated cells 143 were stained with anti-CD34-PE, anti-CD31-FITC, anti-CD45-APC or anti-CD34-PE-Cy7, CD31-BV510, anti-144 Glycophorin A, anti-CD43-FITC, anti-CD45-APC antibodies (all from BD Biosciences) and 7-actinomycin D, 145 and analyzed using a FACS Canto flow cytometer<sup>9,29,39-41</sup>. Colony-forming unit (CFU) assays were performed 146 at day 10 and 15 of EB differentiation by plating 60x10<sup>4</sup> EB cells onto serum-free methylcellulose H4435 147 (Stem Cell Technologies). Colonies were scored after 12 days<sup>9,29,42-44</sup>.

148

### 149 Cell cycle and apoptosis analysis

For cell cycle analysis of hESC-derived HEPs and CD45<sup>+</sup> cells, day 15 EBs were dissociated and harvested cells were fixed overnight in 70% ice-cold ethanol. Cells were then washed in PBS and incubated with anti-CD31-FITC, anti-CD34-PE-Cy7 and anti-CD45-APC antibodies for 15 min. Cells were then suspended in propidium iodide-containing buffer and acquired-analysed on a FACS Canto-II using Modfit LT4.0 software, discriminating between quiescent cells (G0/G1), cycling cells (S-phase) and G2/M cells<sup>45,46</sup>. Apoptosis was assessed with the Annexin-V apoptosis detection kit (BD Biosciences)<sup>16</sup>.

156

### 157 Human ESC-OP9 co-cultures

158 hESC-OP9 co-cultures were performed as described<sup>47,48</sup>. OP9 stroma was prepared by plating OP9 cells in 159 gelatin-coated dishes, and allowing them to overgrow as a monolayer. hESCs were prepared as a suspension 160 of small aggregates using collagenase IV:Dispase. One-tenth of this suspension was plated on top of the 8-161 day overgrown OP9 stroma. Media was replaced on the next day and one-half volume media changes were 162 performed every other day thereafter. Hematopoietic differentiation was assessed by flow cytometry at day 163 9 of co-culture. Accordingly, hESC-OP9 co-cultures were treated with collagenase IV/TrypLE and cells were 164 dissociated and filtered through a 70-µm strainer. Cell suspensions were stained with anti-mouse CD29-165 FITC and anti-human CD34-PE and CD45-APC antibodies. The proportion of HEPs (CD34+CD31+CD45-), 166 and total blood cells (CD45<sup>+</sup>) was analyzed within the CD29<sup>-</sup> human ESC-derived cell population. Hemogenic 167 and endothelial HEPs were distinguished based on CD34 and CD43 expression<sup>40</sup>.

168

### 169 Culture of FACS-isolated HEPs in MS5 stroma or liquid culture

Day 9 human hESC-OP9 co-cultures were dissociated as above and both CD45+ cells and HEPs were analyzed. FACS-purified HEPs (CD29-CD34+CD31+CD45-) were plated onto MS5 stroma or in liquid culture for 30 or 16 days, respectively, in DM with hematopoietic cytokines (50 ng/mL SCF, 50 ng/mL Flt3L, 10 ng/mL IL-3,20 ng/mL IL-7). The medium was changed every 7 days, and the emergence of CD45+ hematopoietic cells was analyzed by FACS.

175

### 176 Endothelial differentiation of HEPs

HEPS (2×10<sup>4</sup>) from day 9 human hESC-OP9 co-cultures were seeded onto 0.1% gelatin-coated plates in
complete EGM-2 medium with microvasculature supplements (Lonza) for 7 days. Cells were then fixed,
permeabilized and stained with rabbit anti-human VE-cadherin (Cayman), mouse anti-human eNOS (BD
Biosciences), and mouse anti-human vWF (DAKO) followed by Alexa488-conjugated anti-rabbit or Cy3-

181 conjugated anti-mouse (Jakson Immunoresearch) antibodies. Nuclei were counterstained with DAPI. Images

182 were obtained using an inverted fluorescence microscope. Day 7 differentiating cells were trypsinized and

183 cell suspensions were stained with anti-human CD31-FITC and CD144-PerCP-Cy5.5 antibodies.

184

### 185 Mouse transplantation and analysis of hematopoietic-endothelial engraftment

NOD/LtSz-scid IL-2Rγ<sup>-/-</sup> (NSG) mice were housed under sterile conditions. The Animal Care Committee approved all mouse protocols. Briefly, cord bood-derived CD34<sup>+</sup> HSPCs (3×10<sup>4</sup> cells) or cells from day 15 EBs (5×10<sup>5</sup> cells) were intra-bone marrow (BM)-transplanted as described<sup>49</sup>. Animal health was monitored throughout the entire experiment. Mice were killed 10 weeks after transplantation and cell suspensions were analyzed by FACS for human chimerism using anti-HLA-ABC-FITC, anti-CD31-PE, CD144-PerCP-Cy5.5, and anti-CD45-APC antibodies.

192

### 193 Statistical analysis

All data are expressed as mean±SEM. Statistical comparisons were performed using the GraphPad Prism software with the nonparametric Mann-Whitney test, two-tailed P-value (95% confidence interval). Statistical significance was defined as a p-value<0.05.

197

Online methods show detailed information about RNA- and Chromatin Immunoprecipitation sequencing andanalysis.

200

### 201 **RESULTS**

### 202 **Co-expression of A4M and MA4 does not hijack pluripotency**

203 We showed very recently that only 45% of t(4;11)+ B-ALL patients express the reciprocal fusion A4M, 204 whereas MA4 is consistently expressed in all t(4:11)+ B-ALL patients (Fig1A)<sup>18-20</sup>. Here, we generated 205 transgenic hESC lines expressing "MA4 alone", "A4M alone" or MA4+A4M (double fusion, Fig1B, S1B). EV 206 (control)- and MA4-hESCs were established by G418 selection<sup>9</sup>. G418-resistant EV- or MA4-expressing 207 hESCs were then transduced with A4M/dTo-expressing lentiviruses and >90% transduction efficiency was 208 achieved. Transgenic hESC lines were maintained for >50 passages and retained human ESC-like 209 morphology (Fig1B, left), transgene expression (Fig1B, right), and expression of pluripotency-associated 210 transcription factors (Fig1C) and surface markers (Fig1D). All hESC genotypes formed teratomas in NSG 211 mice (data not shown)<sup>9, 50</sup>. Thus, (co-)expression of A4M and/or MA4 is compatible with hESC pluripotency.

212

### A4M and MA4 co-operate to promote HEPs emergence and enhance blood production

214 Hematopoietic differentiation was assessed using two distinct and well-established differentiation systems: 215 EB formation<sup>43,47</sup> (Fig2) and OP9 co-culture<sup>47,48</sup> (Fig3). During differentiation, a population of primitive HEPs 216 arises, which is responsible for further hematopoietic and endothelial commitment<sup>10,30</sup> (Fig2A,3A). We 217 investigated whether co-expression of A4M and MA4 impacts hESC-derived hematopoiesis by analyzing the 218 emergence of HEPs during EB development in hESCs individually expressing the single fusions or the double 219 fusion. We observed a pronounced (~5-10-fold; p<0.05) increase in HEPs at day 7 and 10 of development in 220 EBs expressing the double A4M and MA4 fusion over single fusions (Fig2B, upper-left panel). We next 221 assessed whether co-expression of A4M and MA4 influences subsequent hematopoietic commitment of 222 HEPs. The kinetics of emergence and output of both total CD45<sup>+</sup> hematopoietic cells and CD45<sup>+</sup>CD34<sup>+</sup> 223 hematopoietic progenitors was faster (EB day 10) from double fusion-expressing hESCs than from equivalent 224 single fusion-expressing cells, achieving a 2-3-fold higher hematopoietic output by day 15 of EB development (Fig2B). Furthermore, double fusion-expressing HEPs massively accelerated (EB day10) the emergence of clonogenic hematopoietic progenitors as compared to single fusion-expressing HEPs (Fig2B, bottom-right panel). According to our previous work, if the kinetics of hEB differentiation are extended allowing for a continuum HEP-to-blood transition, MA4-expressing hEBs display an enhanced HEP production coupled to an impaired blood output (EB day 20, Fig S2A) and clonogenic potential (EB day 15, Fig 2B). We confirmed stable expression of ectopic MA4 and A4M upon EB differentiation, supporting the link between genotype and phenotype (Fig2C).

232

233 We also investigated hematopoietic differentiation using the OP9 differentiation system (Fig3A,B), and by 234 plating FACS-sorted HEPs in either hematopoietic liquid culture (Fig3C) or onto MS5 feeders (Fig3D). After 235 10 days on OP9 stroma, double fusion-expressing hESCs yielded a 10-fold higher number of CD45+ 236 hematopoietic cells than did single fusion-expressing hESCs (Fig3B). Moreover, when HEPs were FACS-237 sorted from day 9 OP9 co-cultures and allowed to differentiate into CD45+ blood cells, the yield of CD45+ 238 cells was up to 60-fold higher in double fusion-expressing HEPs than in single fusion-expressing HEPs. 239 (Fig3C,D). Encouraged by these results, we next investigated whether ectopic expression of both A4M and 240 MA4 confers in vivo engraftment capacity to hESC-derived hematopoietic derivatives. To do this, we 241 transplanted 5×10<sup>5</sup> hESC hematopoietic derivatives from each genotype into myeloablated NSG mice<sup>4,43,47</sup>, 242 finding that, despite regulating hematopoietic development in vitro, double fusion-expression did not confer 243 in vivo engraftment to hESC hematopoietic derivatives (Fig2D).

244

The increased hematopoietic output of double fusion-expressing hESCs might be the consequence of transgene-mediated proliferation/survival of the emerging HEPs or CD45+ cells. To address this, we analyzed cell cycle distribution (FigS2B) and apoptosis (FigS2C) within both HEPs and the CD45+ cell population. No differences in the proportion of either cycling HEPs or CD45+ cells were detected between genotypes (25–36% for HEPs and 35–41% for CD45+ cells; **FigS2B**). Apoptotic levels were similarly low between the different genotypes of HEPs (6–8%) and CD45+ cells (5–7%) (**FigS2C**). Collectively, these results show that A4M cooperates with MA4 to induce HEP specification and blood commitment, without hijacking proliferation or survival of HEPs.

253

### 254 A4M and MA4 co-operate to enhance endothelial cell fate from HEPs

255 We next addressed the developmental impact of A4M in endothelial maturation from HEPs<sup>10,47</sup>. We 256 hypothesized that co-expression of A4M and MA4 in HEPs may (i) concomitantly promote subsequent 257 endothelial and hematopoietic commitment or (ii) skew the hemato-endothelial commitment in favor of 258 hematopoiesis. To test this, we analyzed the ability of HEPs to differentiate into mature endothelial cells. 259 OP9-hESC co-cultures were dissociated on day 9 of development and HEPs were FACS-sorted and cultured 260 for a week in endothelial-promoting conditions (Fig4A). The expression of the mature endothelial markers 261 VE-cadherin (CD144), vWF, eNOS and CD31 was then analyzed. Irrespective of the genotype, HEPs 262 cultured in endothelial conditions attached, became spindle-shaped, and formed VE-Cad+ endothelial-like 263 structures co-expressing eNOS, vWF and CD31 (Fig4B,C, top panel). However, double fusion-expressing 264 HEPs were more prone to differentiate into mature endothelial cells than single fusion-expressing HEPs. 265 Accordingly, they yielded a 20-fold higher number of VE-Cad+ endothelial-like structures (Fig4C, top panel) 266 and CD144+CD31+ endothelial cells (Fig4C, bottom panel). Interestingly, endothelial cells 267 (HLA.ABC+CD31+CD34+CD144+CD45-CD43-) were found in the BM of mice transplanted with double fusion-268 expressing hESC blood derivatives at levels ~4-fold higher than in mice transplanted with single fusion-269 expressing cells (Fig4D).

270

Within CD34+CD31+CD45-HEPs, two subpopulations of phenotypically and functionally distinct HEPs can be distinguished based on the expression of CD34 and CD43: hemogenic HEPs (CD34<sup>low/+</sup>CD43+CD45-) and endothelial HEPs (CD34<sup>++</sup>CD43<sup>-</sup>CD45<sup>-</sup>) (**Fig5A**)<sup>40,48,51</sup>. We thus analyzed the contribution of both HEP populations to the superior hematopoietic and endothelial differentiation observed in double fusionexpressing HEPs. Co-expression of A4M and MA4, but not single fusions, robustly enhanced the emergence of both endothelial and hemogenic HEPs (**Fig5B,C**). The identity of hemogenic and endothelial HEPs was confirmed by the specific expression of early hematopoietic and endothelial master genes (**Fig5D**). Thus, A4M cooperates with MA4 to promote hematopoietic and endothelial cell fate.

279

# Genome-wide transcriptomic and H3K79 methylation profiles support the developmental cooperation between A4M and MA4

282 To identify patterns of gene expression that might molecularly explain the functional co-operation between 283 A4M and MA4 in hematopoietic specification, we performed RNA-seg analysis on FACS-purified EV-, MA4, 284 A4M- and double fusion-expressing HEPs from day 15 hEBs. Fig6A shows a heatmap representation of the 285 hierarchical clustering of the 335 genes differentially expressed between the four genotypes (TableS2). 286 There is a clear transcriptomic transition towards a hematopoietic/endothelial gene signature from EV-HEPs 287 to double-fusion-expressing HEPs. Single fusion-expressing HEPs clustered interspersed between EV and 288 double-fusion HEPs. The biological functions affected by genes differentially expressed in MA4-, A4M- and 289 double fusion-expressing HEPs relative to EV were classified by IPA software<sup>47,52</sup> and among the top 290 significant enriched functional categories were "hematological system development and function", "cancer" 291 and "hematological disease" (Fig6B). Statistical (-log(p-value)) power shows distant effects of MA4 and A4M; 292 however, co-expression of both fusions seems to establish a molecular balance/developmental cooperation 293 in promoting blood-endothelial specification from hPSCs. Strikingly, biofunctions specifically associated to 294 hematological lymphoid malignancies (not with non-hematological cancer) were predicted to be activated 295 (positive z-score) exclusively in double fusion-expressing HEPs, further suggesting a molecular cooperation 296 between MA4 and A4M in development and infant leukemia. (Fig6C).

297 The C-terminal-partners of MLL fusions normally interact with the histone methyltransferase DOT1L, which 298 is the sole histone methyltransferase catalyzing histone 3 lysine 79 (H3K79) methylation, a chromatin 299 modification widely associated with the dysregulated expression of HOX-A cluster genes in MLL leukemias 300 <sup>13, 53</sup>. We thus performed genome-wide ChIP-seg analysis of the H3K79 trimethylation (H3K79me3) profiles 301 in control, MA4-, A4M- and double fusion-expressing hESC-derived blood derivatives (Fig7,S3A, TableS3). 302 In line with the RNA-seg data, functional analysis of the differential H3K79me3 peaks specific for double 303 fusion-expressing cells revealed significant GO functional categories associated with "definitive 304 hematopoiesis", "myeloid and erythroid differentiation/homeostasis" and "endothelial cell development" 305 (Fig7A,S3B). This further supports the developmental co-operation between A4M and MA4 in promoting 306 hemato-endothelial specification.

307

308 Finally, we analysed the H3K79me3 profiles at genomic loci of the classical MLL target genes reported by 309 Guenther et al<sup>54</sup>. Non-HOX-A classical MLL targets such as RUNX1, LMO2, ADMA10, and KDM6A showed 310 a slight although non-significant, enrichment of H3K79me3 in MA4-expressing hESCs, validating our ChIP-311 seq approach (Fig7B). However, enrichment of H3K79me3 in HOX-A cluster genes was observed 312 exclusively in A4M-expressing cells although it was statistically significant only in double fusion-expressing 313 differentiating hESCs (FDR<0.1) (Fig7C). As such, HOX-A genes were up-regulated in double-fusion-314 expressing hematopoietic clonogenic progenitors (FigS3C). No differential enrichment of the repressive 315 H3K4me2/3 mark was observed in either HOX-A or non-HOX genes in double fusion-expressing cells 316 (FigS4). Collectively, these data suggest that the deregulated expression of HOX-A genes in MLL leukemias 317 may be imposed by the reciprocal A4M fusion through a H3K79 methyltransferase activity. In support of this, 318 a recent RNA-seg study performed in 42 infants with t(4:11)+ B-ALL enrolled in the Interfant treatment 319 protocol, reveal that 45% of t(4;11)+ patients express the A4M fusion, and that HOX-A cluster genes are

exclusively expressed in this *AF4-MLL*-expressing subgroup of t(4;11)+ patients, who in fact display a
 significant more favorable clinical outcome<sup>19</sup>.

322

# 323 DISCUSSION 324

325 From an etiological and pathogenesis standpoint, infant cancer is distinct to adult cancer and should be 326 studied as a developmental disease<sup>4,7,16</sup>. A biologically and clinically intriguing infant cancer is the t(4;11)+ 327 B-ALL, which is associated with a dismal outcome<sup>4,21,23</sup>. Evidence in support of its prenatal origin comes from 328 studies in monozygotic twins and archived blood spots, providing compelling evidence of a single prenatal 329 cell as the origin for t(4;11)<sup>5</sup>, and also from recent genome-wide studies demonstrating that this infant 330 leukemia has one of the lowest frequencies of somatic mutations of any sequenced cancer<sup>55</sup>. The stable 331 genome of these patients suggests that in infant developmental cancer, one "big-hit" might be sufficient for 332 overt disease, supporting a key contribution of the prenatal cell-of-origin during a critical developmental 333 window of stem cell vulnerability in leukemogenesis. However, despite its aggressiveness and short latency, 334 our current understanding about its etiology, pathogenesis and cellular origin is still limited<sup>2,4,16,52</sup>. Importantly, 335 a recently developed xenograft model which represents the most bona fide model for t(4;11)+ B-ALL so far, 336 has revealed the instructive role of MLL-Af4 in cord blood-derived CD34+ cells<sup>14</sup>.

337

Studies using primary cells from t(4;11)+ B-ALL patients are incapable of addressing the developmental genesis of the hematopoietic system. Recent data suggest that fetal liver lymphoid-primed multipotent progenitor may provide the developmental prerequisites for the initiation of t(4;11)+/MLL-AF4 infant leukemia<sup>56</sup>. Because leukemogenesis manifests as a blockage or altered cell differentiation, the hematopoietic differentiation of hESCs may represent a promising *in vitro* model to study the onset of hematopoiesis and the earliest events leading to the specification of the hematopoietic cells<sup>36</sup>. Previous studies have addressed the oncogenic role of leukemic fusion genes in hESC-derived hematopoiesis<sup>57,5859</sup>. We previously explored the developmental impact of the pre-natal fusion MA4 in hESC hemato-endothelial development<sup>10</sup>, and found that MA4 expression promotes the emergence of endothelial-primed HEPs and further endothelial commitment, but hijacks the specification of hemogenic-primed HEPs, impairing hematopoietic output<sup>10</sup>.

349

350 The functional and molecular contribution of the reciprocal fusion genes resulting from the derivative 351 translocated chromosomes remains obscure in cancer<sup>18,60</sup>. The MA4 fusion is always expressed in t(4;11)+B-352 ALL patients, whereas the reciprocal fusion A4M is expressed in only 45-50% of the patients<sup>18,60,19,20</sup>. Here, 353 we took advantage of well-established hESC-based differentiation systems to study whether the A4M fusion 354 cooperates with MA4 during early human hematopoietic and endothelial development. Co-expression of A4M 355 and MA4 strongly promoted the emergence of HEPs, both endothelial-primed and hemogenic-primed. 356 Moreover, the double fusion-expressing HEPs specified into significantly higher numbers of both 357 hematopoietic and endothelial cells, irrespective of the in vitro differentiation protocol used and without 358 affecting survival or proliferation, indicating a functional (developmental) co-operation between MA4 and A4M 359 fusions during human hematopoietic development. This notion was confirmed by genome-wide 360 transcriptomic analysis of differentiating HEPs. These developmental biology studies support previous 361 evidence suggesting that A4M contributes to the pathobiology of t(4;11)+ B-ALL. Accordingly, Bursen<sup>11</sup> 362 reported that A4M-transduced murine hematopoietic stem cells (HSCs) developed pro-B-ALL, whereas co-363 transduction with MA4 and A4M resulted in mixed lineage leukemia. Moreover, studies from Milne's 364 laboratory demonstrated that RUNX1 is directly activated by MA4 and the RUNX1 protein interacts with the 365 A4M protein, suggesting a mechanism of co-operation between the two fusion genes at the molecular level<sup>25</sup>. 366

367 In the embryo, definitive hematopoiesis cannot occur in the absence of endothelial cell development.

368 Definitive HSCs in both mouse and human emerge from the hemogenic endothelium by a process known as

369 endothelial-to-hematopoietic transition<sup>61</sup>. Hematopoietic differentiation of hESCs occurs through the 370 generation of HEPs, from which then originate both endothelial and hematopoietic cells. Here, co-expression 371 of A4M and MA4 in HEPs concomitantly promoted endothelial and hematopoietic commitment rather than 372 skewing the hemato-endothelial commitment in favor of one lineage over the other. This finding is important 373 because beyond their pathogenic role in acute leukemias, the MLL gene is implicated in endothelial cell 374 maturation, and endothelial dysfunction was recently linked to disease outcome in childhood leukemias<sup>31,32</sup>. 375 Furthermore, other leukemia fusion oncogenes as well as lymphoma-specific genetic aberrations have been 376 found in endothelial cells from chronic myeloid leukemia and B-cell lymphoma patients<sup>10,43,44</sup>, suggesting that 377 endothelial cells may be part of the neoplastic clone. Also, BM-derived mesenchymal stem cells (BM-MSCs) 378 from infant t(4;11) + B-cell ALL were recently found to harbor and express the t(4;11) translocation<sup>33</sup>. The 379 existence of a common embryonic precursor for MSCs and endothelial cells has been recently demonstrated 380 by hESC-directed differentiation<sup>10,45</sup>. The finding of such a common embryonic precursor, and the presence 381 of t(4:11) in both leukemic blasts and BM-MSCs of infant patients, suggests that the t(4:11) translocation 382 arises and has a developmental impact on early pre-hematopoietic precursors. As a technical caveat, it is 383 important to emphasize that MA4 and A4M were sequentially transduced to allow for antibiotic selection and 384 homogeneously-transduced hESC cultures. However, in double-fusion-expressing differentiating blood cells, 385 MA4 was never individually expressed in the absence of A4M. When hematopoietic differentiation of hESCs 386 was induced by EB formation both fusions were readily co-expressed, ruling out a biased functional 387 phenotype driven by the sequential expression of each transgene in distinct developmental windows.

388

389

390 Mechanistically, a putative function of A4M is to activate chromatin, rendering a chromatin landscape similar 391 to that during stem cell development. It is currently unknown how A4M is able to reprogram chromatin, but it 392 does contain the SET domain disrupted from its "specification domain", the N-terminal portion of MLL, which 393 binds to MEN1 and LEDGF, shaping the gene targeting module of the MLL gene. When A4M is expressed, 394 the N-terminal portion is substituted by the AF4 N-terminus, which is the crucial domain (AF4N) that binds to 395 and strongly activates RNA polymerase II (RNAP II) for transcriptional elongation. Overexpression of either 396 AF4. AF4N or the fusion protein A4M induces robust RNAP II-dependent gene transcription by overwriting 397 the elongation control process in a dominant fashion<sup>62-64</sup>. Since gene transcription per se and in particular 398 "sterile" transcription is a powerful mechanism for chromatin activation, A4M could potentiate MA4 to skew 399 normal and leukemic hematopoietic cell fate decisions. This also explains why MA4 has a more prominent 400 role in the disease than the reciprocal A4M. If A4M functioned to initiate this process only by itself, then it 401 would become obsolete after fulfilling the "chromatin opening job". However, transcription factors like MA4, 402 RUNX1 or others then establish the transcriptional program leading to leukemogenesis. This is reflected in 403 the enhanced hematopoietic potential of double fusion-expressing hESCs and the enriched H3K79me3 404 activation mark in HOX-A cluster genes exclusively when MA4 and A4M are co-expressed. Thus, A4M 405 prepares other transcription factors to become oncoproteins.

406

407 Molecularly, C-terminal-partners of MLL fusions (AF4, AF9, ENL) interact with DOT1L, which is the sole 408 histone methyltransferase catalyzing H3K79 methylation, a chromatin modification widely associated with the 409 dysregulated expression of HOX-A gene cluster in MLL-rearranged leukemias<sup>13,53</sup>. Here, ChIP-seq analysis 410 of differentially enriched H3K79me3 genomic regions confirmed a hematopoietic/endothelial cell 411 differentiation signature in double fusion-expressing HEPs, and revealed a significant enrichment of H3K79 412 methylated regions specifically associated with HOX-A cluster MLL target genes (but not to non-HOX-A MLL 413 targets) in double fusion-expressing differentiating hematopoietic cells. This is in line with the recently found 414 significant positive correlation between the upregulation of the HOX-A gene cluster and the expression of 415 A4M in primary t(4;11)+ infant B-cell ALL samples, and with previous studies identifying that approximately 416 one-half of t(4;11)+ patients do not have an activated HOX-A signature<sup>20,65,66</sup>. This may explain why MA4

failed recently to bind to *HOX-A* genes to regulate *HOXA* gene expression<sup>14</sup>. Collectively, MA4 and A4M might cooperate through a complex molecular interaction to control *HOX-A* gene regulation<sup>25</sup>. In sum, we describe a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic development, and demonstrate how hESC-based hematopoietic differentiation represents a promising system to explore the developmental impact of the chimeric proteins resulting from chromosomal translocations, which remains obscure in human leukemia.

AUTHOR CONTRIBUTION: C.B. conceived the study, designed and performed experiments and analyzed
data. P.M. conceived the study, designed experiments, analyzed data and wrote the manuscript. F.C.N.,
X.W., R.V.M., F.G-A., H.R.H., V.A., P.J.R., D.A., L.E., R-T-R., A.A-D., J.dB. performed experiments and
analyzed data. I.V., A.B., B.G., and R.M. contributed intellectually and financially.

427

428 **ACKNOWLEDGMENTS.** Financial support for this work was obtained from the European Research Council 429 (CoG-2014-646903 and PoC-2018-811220) and the Generalitat de Catalunya (SGR330 and PERIS 2017-430 2019) to PM, the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF2016-431 76758-R) to PM and IV, the Spanish Association against cancer (AECC-CI-2015) to CB, the Health Institute 432 Carlos III (ISCIII/FEDER, PI17/01028 and PI17/01028) to CB and PJR, the NIHR GOSH BRC and Great 433 Ormond Street Hospital Children's Charity to J.dB, and Bloodwise and Cancer Research UK to BG. RM and 434 PM were also supported by the Deutsche José Carreras Leukämie Stiftung. PM also acknowledges financial 435 support from the Obra Social La Caixa-Fundaciò Josep Carreras. R-T-R is supported by a fellowship from the Spanish Association of Cancer Research (AECC). RV-M is supported by a Torres Quevedo fellowship 436 437 by Spanish Ministry of Science and Innovation (PTQ-16-08623). P.M is an investigator of the Spanish Cell 438 Therapy cooperative network (TERCEL).

439

440 **CONFLICT OF INTEREST DISCLOSURE:** The authors have nothing to disclose. 441 442 443 444 445 446 447 REFERENCES 448 Milne TA. Mouse models of MLL leukemia: recapitulating the human disease. Blood. 1. 449 2017;129(16):2217-23. 450 451 Montes R, Ayllon V, Prieto C, Bursen A, Prelle C, Romero-Moya D, et al. Ligand-independent FLT3 2. 452 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells. Leukemia. 2014;28(3):666-74. 453 454 455 Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, et al. Targeting FLT3 3. 456 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005;106(7):2484-90. 457 458 Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam RW, Marschalek R, et al. Revisiting the biology of 4. 459 infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood. 2015;126(25):2676-85. 460 461 Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC, et al. In utero rearrangements 5. in the trithorax-related oncogene in infant leukaemias. Nature. 1993;363(6427):358-60. 462 463 464 Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 6. 2006;6(3):193-203. 465 466 467 7. Bueno C, Montes R, Catalina P, Rodriguez R, Menendez P. Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement. Leukemia. 468 469 2011;25(3):400-10. 470 471 Barrett NA, Malouf C, Kapeni C, Bacon WA, Giotopoulos G, Jacobsen SE, et al. MII-AF4 Confers 8. 472 Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development. Cell Rep. 473 2016;16(4):1039-54. 474 475 Bueno C, Ayllon V, Montes R, Navarro-Montero O, Ramos-Mejia V, Real PJ, et al. FLT3 activation 9. 476 cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs. Blood. 477 2013;121(19):3867-78, S1-3. 478

479 10. Bueno C, Montes R, Melen GJ, Ramos-Mejia V, Real PJ, Ayllon V, et al. A human ESC model for
480 MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification. Cell Res.
481 2012;22(6):986-1002.

483
483
484
484
484
485
485
485
485
485
485
485
485
485
485
485

486
487
487
488
12. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-in model
487
488
488

489
43. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles
490
491
491

492 14. Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, et al. Instructive Role of MLL-Fusion
493 Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 2016;30(5):737494 49.
495

496 15. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN, et al. A conditional model of MLL497 AF4 B-cell tumourigenesis using invertor technology. Oncogene. 2006;25(22):3093-103.
498

Montes R, Ayllon V, Gutierrez-Aranda I, Prat I, Hernandez-Lamas MC, Ponce L, et al. Enforced
expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell
function and clonogenic potential but is not sufficient to initiate leukemia. Blood. 2011;117(18):4746-58.

Tamai H, Miyake K, Takatori M, Miyake N, Yamaguchi H, Dan K, et al. Activated K-Ras protein
accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia.
2011;25(5):888-91.

18. Kowarz E, Burmeister T, Lo Nigro L, Jansen MW, Delabesse E, Klingebiel T, et al. Complex MLL
rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele. Leukemia. 2007;21(6):12328.

Agraz-Doblas A. Bueno C., Bashford-Rogers R., Anindita R., Schneider P., Bardini M., Ballerini P.,
Cazzaniga G., Moreno T., Revilla C., Gut M., De Lorenzo P., Valsecchi MG, Roberts I, Pieters R, Varela I.,
Menendez P., Stam R.W. Unravelling the cellular origin and clinical prognosis markers of infant B-cell acute
lymphoblastic leukemia using genome-wide analysis. Haematologica. 2019;in press.

516 20. Trentin L, Giordan M, Dingermann T, Basso G, Te Kronnie G, Marschalek R. Two independent gene 517 signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur J Haematol. 2009;83(5):406-19.

518
519 21. Kumar AR, Yao Q, Li Q, Sam TA, Kersey JH. t(4;11) leukemias display addiction to MLL-AF4 but not
520 to AF4-MLL. Leuk Res. 2011;35(3):305-9.

521
522 22. Sanders DS, Muntean AG, Hess JL. Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias?
523 Leuk Res. 2011;35(3):299-300.

524

Prieto C, Marschalek R, Kuhn A, Bursen A, Bueno C, Menendez P. The AF4-MLL fusion transiently
 augments multilineage hematopoietic engraftment but is not sufficient to initiate leukemia in cord blood
 CD34(+) cells. Oncotarget. 2017;8(47):81936-41.

Rego EM, Pandolfi PP. Reciprocal products of chromosomal translocations in human cancer
 pathogenesis: key players or innocent bystanders? Trends Mol Med. 2002;8(8):396-405.

- 532 25. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, et al. RUNX1 is a key target in t(4;11)
  533 leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep.
  534 2013;3(1):116-27.
- 536 26. Menendez P, Bueno C, Wang L. Human embryonic stem cells: A journey beyond cell replacement 537 therapies. Cytotherapy. 2006;8(6):530-41.

538

556

- Romero-Moya D, Santos-Ocana C, Castano J, Garrabou G, Rodriguez-Gomez JA, Ruiz-Bonilla V,
  et al. Genetic Rescue of Mitochondrial and Skeletal Muscle Impairment in an Induced Pluripotent Stem Cells
  Model of Coenzyme Q10 Deficiency. Stem Cells. 2017;35(7):1687-703.
- 543 28. Menendez P, Vargas A, Bueno C, Barrena S, Almeida J, De Santiago M, et al. Quantitative analysis
  544 of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia. 2004;18(3):491-8.
  545
- S46 29. Ramos-Mejia V, Melen GJ, Sanchez L, Gutierrez-Aranda I, Ligero G, Cortes JL, et al. Nodal/Activin
  signaling predicts human pluripotent stem cell lines prone to differentiate toward the hematopoietic lineage.
  Mol Ther. 2010;18(12):2173-81.
- Wang L, Li L, Shojaei F, Levac K, Cerdan C, Menendez P, et al. Endothelial and hematopoietic cell
   fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties.
   Immunity. 2004;21(1):31-41.
- 554 31. Diehl F, Rossig L, Zeiher AM, Dimmeler S, Urbich C. The histone methyltransferase MLL is an upstream regulator of endothelial-cell sprout formation. Blood. 2007;109(4):1472-8.
- 32. Hatzipantelis ES, Athanassiou-Metaxa M, Gombakis N, Tzimouli V, Taparkou A, Sidi-Fragandrea V,
  et al. Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in
  children with acute lymphoblastic leukemia. Acta Haematol. 2011;125(3):130-5.
- Menendez P, Catalina P, Rodriguez R, Melen GJ, Bueno C, Arriero M, et al. Bone marrow
  mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion
  gene. J Exp Med. 2009;206(13):3131-41.
- 565 34. Ramos-Mejia V, Fernandez AF, Ayllon V, Real PJ, Bueno C, Anderson P, et al. Maintenance of 566 human embryonic stem cells in mesenchymal stem cell-conditioned media augments hematopoietic 567 specification. Stem Cells Dev. 2012;21(9):1549-58.
- Sanchez L, Gutierrez-Aranda I, Ligero G, Martin M, Ayllon V, Real PJ, et al. Maintenance of human
  embryonic stem cells in media conditioned by human mesenchymal stem cells obviates the requirement of
  exogenous basic fibroblast growth factor supplementation. Tissue Eng Part C Methods. 2012;18(5):387-96.

- 572
  573 36. Bueno C, Montes R, Martin L, Prat I, Hernandez MC, Orfao A, et al. NG2 antigen is expressed in
  574 CD34+ HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the
  575 target cell where leukemogenesis is triggered? Leukemia. 2008;22(8):1475-8.
- 576
  577 37. Castano J, Menendez P, Bruzos-Cidon C, Straccia M, Sousa A, Zabaleta L, et al. Fast and efficient
  578 neural conversion of human hematopoietic cells. Stem Cell Reports. 2014;3(6):1118-31.
  579
- 38. Munoz-Lopez A, Romero-Moya D, Prieto C, Ramos-Mejia V, Agraz-Doblas A, Varela I, et al.
  Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into
  Pluripotency. Stem Cell Reports. 2016;7(4):602-18.
- 39. Bueno C, Sardina JL, Di Stefano B, Romero-Moya D, Munoz-Lopez A, Ariza L, et al. Reprogramming
  human B cells into induced pluripotent stem cells and its enhancement by C/EBPalpha. Leukemia.
  2016;30(3):674-82.
- 40. Giorgetti A, Castano J, Bueno C, Diaz de la Guardia R, Delgado M, Bigas A, et al. Proinflammatory
  signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro. Exp Hematol.
  2017;45:85-93 e2.
- Menendez P, Wang L, Chadwick K, Li L, Bhatia M. Retroviral transduction of hematopoietic cells
   differentiated from human embryonic stem cell-derived CD45(neg)PFV hemogenic precursors. Mol Ther.
   2004;10(6):1109-20.
- 595
  596 42. Bueno C, Roldan M, Anguita E, Romero-Moya D, Martin-Antonio B, Rosu-Myles M, et al. Bone
  597 marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune
  598 properties and do not contribute to the pathogenesis of the disease. Haematologica. 2014;99(7):1168-75.
- 43. Ramos-Mejia V, Navarro-Montero O, Ayllon V, Bueno C, Romero T, Real PJ, et al. HOXA9 promotes
   hematopoietic commitment of human embryonic stem cells. Blood. 2014;124(20):3065-75.
- 44. Toscano MG, Navarro-Montero O, Ayllon V, Ramos-Mejia V, Guerrero-Carreno X, Bueno C, et al.
   SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic
   stem cells. Mol Ther. 2015;23(1):158-70.
- 606
  607
  45. Bueno C, Montes R, Menendez P. The ROCK inhibitor Y-27632 negatively affects the
  608 expansion/survival of both fresh and cryopreserved cord blood-derived CD34+ hematopoietic progenitor
  609 cells: Y-27632 negatively affects the expansion/survival of CD34+HSPCs. Stem Cell Rev. 2010;6(2):215-23.
  610
- 46. Rubio R, Garcia-Castro J, Gutierrez-Aranda I, Paramio J, Santos M, Catalina P, et al. Deficiency in
  p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates
  leiomyosarcoma in vivo. Cancer Res. 2010;70(10):4185-94.
- 614
- 47. Ayllon V, Bueno C, Ramos-Mejia V, Navarro-Montero O, Prieto C, Real PJ, et al. The Notch ligand
  DLL4 specifically marks human hematoendothelial progenitors and regulates their hematopoietic fate.
  Leukemia. 2015;29(8):1741-53.
- 618

48. Vodyanik MA, Slukvin, II. Hematoendothelial differentiation of human embryonic stem cells. Curr
Protoc Cell Biol. 2007;Chapter 23:Unit 23 6.

49. Bueno C, Montes R, de la Cueva T, Gutierrez-Aranda I, Menendez P. Intra-bone marrow
transplantation of human CD34(+) cells into NOD/LtSz-scid IL-2rgamma(null) mice permits multilineage
engraftment without previous irradiation. Cytotherapy. 2010;12(1):45-9.

625

626 50. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M, Real PJ, Macia A, et al. Human
627 induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells
628 regardless the site of injection. Stem Cells. 2010;28(9):1568-70.

- 51. Vodyanik MA, Bork JA, Thomson JA, Slukvin, II. Human embryonic stem cell-derived CD34+ cells:
  efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential.
  Blood. 2005;105(2):617-26.
- 633

651

655

659

52. Prieto C, Stam RW, Agraz-Doblas A, Ballerini P, Camos M, Castano J, et al. Activated KRAS
635 Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+
636 HSPC But Is Insufficient to Initiate Leukemia. Cancer Res. 2016;76(8):2478-89.

- 637
  638 53. Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, et al. AF10 regulates
  639 progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell.
  640 2014;26(6):896-908.
- 642 54. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, et al. Aberrant
  643 chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev.
  644 2008;22(24):3403-8.
- 646 55. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic
  647 mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330-7.
  648
- 649 56. Malouf C, Ottersbach K. The fetal liver lymphoid-primed multipotent progenitor provides the 650 prerequisites for the initiation of t(4;11) MLL-AF4 infant leukemia. Haematologica. 2018.
- 57. Peters DG, Klucher KM, Perlingeiro RC, Dessain SK, Koh EY, Daley GQ. Autocrine and paracrine
  effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.
  Oncogene. 2001;20(21):2636-46.
- 58. Ji J, Risueno RM, Hong S, Allan D, Rosten P, Humphries K, et al. Brief report: ectopic expression of
   NUP98-HOXA10 augments erythroid differentiation of human embryonic stem cells. Stem Cells.
   2011;29(4):736-41.
- 59. Tan YT, Ye L, Xie F, Beyer AI, Muench MO, Wang J, et al. Respecifying human iPSC-derived blood
  cells into highly engraftable hematopoietic stem and progenitor cells with a single factor. Proc Natl Acad Sci
  U S A. 2018;115(9):2180-5.
- 663
  664 60. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol.
  665 2011;152(2):141-54.

- 666
  667
  61. Boisset JC, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C. In vivo imaging of
  668 haematopoietic cells emerging from the mouse aortic endothelium. Nature. 2010;464(7285):116-20.
- 670 62. Ahmad K, Scholz B, Capelo R, Schweighofer I, Kahnt AS, Marschalek R, et al. AF4 and AF4-MLL
  671 mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3. Oncotarget.
  672 2015;6(28):25784-800.
- 63. Benedikt A, Baltruschat S, Scholz B, Bursen A, Arrey TN, Meyer B, et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia. 2011;25(1):135-44.
- 678 64. Muck F, Bracharz S, Marschalek R. DDX6 transfers P-TEFb kinase to the AF4/AF4N (AFF1) super
  679 elongation complex. Am J Blood Res. 2016;6(3):28-45.
  680
- 681 65. Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG, et 682 al. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in 683 infants. Haematologica. 2013;98(6):937-44.
- 684
  685
  66. Kuhn A, Loscher D, Marschalek R. The IRX1/HOXA connection: insights into a novel t(4;11)- specific
  686 cancer mechanism. Oncotarget. 2016;7(23):35341-52.
- 687 688

677

### 690 **FIGURE LEGENDS**

Figure 1. Characterization of transgenic human ESCs expressing the reciprocal fusion A4M together with MA4. (A) RNA-seq and qRT-PCR validation revealed that ~45% (11/25) of the patients with t(4;11)+ B-ALL do not express the reciprocal fusion A4M<sup>18</sup>. (B) *Left*, Phase-contrast morphology of representative colonies from each transgenic hESC line. *Right*, RT-PCR confirming expression of both fusions in undifferentiated hESCs. (C) qRT-PCR expression of the pluripotency genes *OCT4*, *SOX2*, *NANOG*, *CRIPTO*, and *DNMT3B*. (D) Representative FACS data confirming expression of the pluripotency surface makers SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81.

698

699 Figure 2. A4M cooperates with MA4 to accelerate human ESC/EB specification towards HEPs and 700 subsequent hematopoietic differentiation. (A) Schematic of EB hematopoietic differentiation of hESCs 701 and end-point analyses. (B) Upper left, specification into HEPs (CD31+CD34+CD45-) is accelerated in double 702 fusion-expressing hESCs. Subsequent differentiation of HEPs into hematopoietic progenitors (upper right) 703 and mature CD45+ blood cells (bottom left) is enhanced in double fusion-expressing HEPs. Bottom right, CFU 704 read-out and scoring (pie charts) confirming an accelerated and enhanced hematopoietic progenitor potential 705 from double fusion-expressing blood derivatives. (C) RT-PCR confirming stable expression of MA4 and A4M 706 upon EB differentiation. (D) Neither MA4- nor double fusion-expressing blood derivatives display in vivo 707 hematopoietic engraftment potential in irradiated NSG mice. Data are presented as mean±SEM from at least 708 three independent experiments. \*p<0.05.

709

Figure 3. Co-expression of MA4 and A4M enhances hematopoietic differentiation of human ESCs in OP9 co-culture. (A) Experimental design of OP9-based hESC differentiation towards HEPs and further hematopoietic commitment of HEPs maintained in either liquid culture for 16 days or in MS5 co-culture for 30 days. (B) Frequency of total CD45+ blood cells after 9 days in OP9 co-culture. (C,D) CD45-CD31+CD34+ HEPs were FACS-purified at day 9 of OP9 co-culture and allowed to differentiate into CD45+ cells in liquid
 culture (**C**) or in MS5 co-culture (**D**). Data represent mean±SEM from independent experiments.

716

717 Figure 4. Enhanced endothelial cell fate from HEPs co-expressing MA4 and A4M. (A) Scheme of HEPs 718 endothelial differentiation and phenotypic characterization. (B) FACS-sorted HEPs from day 9 human ESC-719 OP9 co-cultures were cultured in EGM2 medium for 5 days and analyzed by immunofluorescence for VE-720 cadherin, eNOS and vWF. (C) Top, Endothelial-like structures were identified and guantified based on VE-721 cadherin staining (white dotted-lined areas in B, top panel). Bottom, Frequency of CD45<sup>-</sup>CD31<sup>+</sup>CD144<sup>+</sup> 722 endothelial cells quantified by flow cytometry. (D) In vivo endothelial engraftment potential 723 (HLA.ABC+CD31+CD144+CD45-) analyzed in bone marrow of NSG mice 8 weeks after transplantation of 724 HEPs. Data presented as mean±SEM from 5 independent experiments. \*p<0.05.


725

Figure 5. Co-expression of MA4 and A4M significantly enhances the emergence of both endothelial and hemogenic HEPs. (A) Representative flow cytometry analysis of HEPs with hemogenic (CD45-CD31+CD43+CD34dim/+) and endothelial (CD45-CD31+CD43-CD34++) potential. (B,C) A4M cooperates with MA4 to boost the emergence of both endothelial (B) and hemogenic (C) HEPs. Data presented as mean±SEM from 3 independent experiments. (D) Expression of *RUNX1c* and *Ve-Cad* in hemogenic and endothelial HEPs. \* p<0.05


732

Figure 6: Transcriptional transition towards a hematopoietic/endothelial gene signature in double fusion-expressing HEPs. (A) Heatmap representation of hierarchical clustering of genes differentially expressed between EV-, single fusions- and double fusion-expressing HEPs. Each column represents a technical replicate from three independent experiments. (B,C) Statistically significant functional categories (B) and cancer/leukemia-associated biofunctions (C) identified using IPA on genes differentially expressed


738	in single fusions-, and double fusion-expressing HEPs relative to EV. They are ranked by z-score. Functional
739	categories associated with "hematological system development and function" and "cardiovascular system
740	development" are shown in bold. All significant biofunctions are associated with blood cell differentiation,
741	homeostasis and migration/movement.
742	
743	Figure 7: H3K79 methylation profiles at genomic loci of MLL targets in MA4-, A4M- and double fusion-
744	expressing human ESC-derived blood derivatives. (A) GO enrichment of differential H3K79me3 peaks
745	specific for double fusion-expressing cells. (B-C) Representative profiles for ChIP-seq using anti-H3K79me <sup>3</sup>
746	antibody at genomic regions of typical non-HOXA ( <b>B</b> ) and HOXA MLL targets ( <b>C</b> ).
747	
748	
749	
750	
751	
752	
753	
754	
755	
756	
757	
758	
759	
760	
761	



### Bueno C et al. Figure 2





Α







### Bueno C et al. Figure 4







С



-log (p-value)


**Cancer Functions** 


	MA4	A4M	MA4-A4M
Lymphatic system tumor	-0.313		2.025
Lymphatic cancer	-0.313		2.025
Lymphocytic neoplasm	-0.313		2.025
Lymphoid cancer	-0.313		2.025
Neoplasia of leukocytes	-0.313		2.025
Hematologic cancer of cells	-0.313		2.016
Lymphoma	-0.313		1.977
Hematologic cancer	-0.537		1.886
Lymphoreticular neoplasm	-0.014		1.854
Neoplasia of cells	-1.116		1.498
Hematopoietic neoplasm	-0.788		1.472
Carcinoma	-1.526	1.464	-0.445
Non-hematological neoplasm	-1.19	1.662	-0.45
ematologic malignantneoplasm	-0.859	1.714	-0.61
Digestive organ tumor	-1.541	-1.231	-1.026


### **Haematological Disease Functions**

	MA4	A4M	MA4-A4M
Thrombus	1.714		0.23
Formation of thrombus	1.067		-0.277
Hematologic cancer of cells	-0.313		2.016
Lymphocytic cancer	-0.313		2.025
Lymphocytic neoplasm	-0.313		2.025
Lymphoid cancer	-0.313		2.025
Lymphoma	-0.313		1.977
Lymphoproliferative disorder	-0.313		2.025
Neoplasia of leukocyte	-0.313		2.025
Hematologic cancer	-0.537		1.886
Hematopoietic neoplasm	-0.788		1.472
Cytopenia	-2.66		
Thrombocytopenia	-2.831		
Hemorrhagic disease	-3.137		

Bueno C et al. Figure 7







### SUPPLEMENTARY LEGENDS AND METHODS

### Chromatin immunoprecipitation Sequencing

One million day 15 hematopoietic differentiating hEB-derived cells were subjected to Chromatin Immunoprecipitation (ChIP) as described <sup>1</sup>. Briefly, formaldehyde crosslinked cell extracts were sonicated using a Bioruptor (Diagenode) with a 0.5-min interval protocol to obtain DNA fragments of 200-500 bp. The chromatin fraction was divided into three parts and incubated overnight with 2 µg of anti-H3K4me3, anti-H3K79me3, or anti-H3 antibodies (Abcam) in RIPA buffer, and precipitated with protein A/G-Sepharose (Amersham). Cross-linkage of the co-precipitated DNA-protein complexes was reversed, and the DNA was sequenced at the CRG-CNAG Genomics Facility. Paired-end 50 bp ChIPseq data reads were generated using a HiSeq 2500 Illumina sequencer. Alignment and peak detection was performed using the ENCODE (phase-3) histone ChIP-seg pipeline specifications. Reads were aligned to the human reference genome (assembly hg19) using BWA<sup>2</sup>, removing all reads with a quality score <30. Peaks were called using MACS2<sup>3</sup> and whole cell extract samples as background samples. Differential analysis of histone mark peaks between experimental groups and the EV control group was performed using DiffBind<sup>4</sup>, with a False Discovery Rate (FDR) cut-off of 0.1. Peaks annotation and Gene Ontology (GO) enrichment were analyzed with ChIP-Enrich package in R<sup>4</sup>, using an FDR threshold of 0.1. ChIP-Seq data is deposited and available at Gene Expression Omnibus (GEO, accession number GSE111263).

### Low-input RNA-seq and bulk RNA-seq on t(4;11)+B-ALL patients

For low-input RNAseq, 50 HEPs were FACS-purified from day 15 EBs into individual wells of a 96-well PCR plate containing lysis buffer (0.2% Triton-X100 and 2.3 U of SUPERase-In RNase Inhibitor; Ambion). Three independent replicates (50 cells/replicate) per condition were analyzed. RNA/cDNA was obtained and amplified as per the SMARTSEQ2 protocol<sup>5,6</sup>. Libraries were prepared for 1

sequencing using the Illumina Nextera XT DNA preparation kit. RNA-seq data was generated using a 50 single-end sequencing protocol. Pooled libraries were sequenced on the Illumina HiSeq 4000 platform. Reads were mapped to the human genome (Ensembl 81) and the ERCC sequences using STAR (version 2.4.2a) with default parameters. HTseq-count<sup>7</sup> was used to count the number of reads mapped to each gene with -s no (non-strand specific mode). Data were normalized for sequencing depth using the size factor from the DESeq2 package (version 1.12.2)<sup>8</sup>. Low-input RNA-seq data is deposited and available at GEO (GSE118947).

Bulk RNA-seq data on t(4;11)+ B-ALL patients was generated on the Illumina HiSeq 2500 platform using a 76 paired-end sequencing protocol and aligned to the human reference genome (hg19) using Tophat<sup>19</sup>. A gene was considered differentially expressed in MA4-A4M+ HEPs when it was >2-fold regulated (p<0.01) compared with the equivalent gene in EV-HEPs. Analysis of functional categories and biofunctions was performed with the genes differentially expressed using Ingenuity Pathway Analysis software (Ingenuity Inc., Redwood City, CA). Potential read pairs supporting the expression of MA4 and A4M fusion transcripts in patient samples were identified manually and with in-house written scripts as pairs in which each read aligned unambiguously to a different gene and which were compatible with the genomic breakpoints that were determined at the DNA level in all the samples. Additionally, RT-PCR with primers corresponding to *AF4* exon3 and *MLL* exon 12 (exons contained in all predicted fusions) was performed in all the samples to confirm the expression of any potential isoform of the reciprocal fusion gene. The identity of the isoform was confirmed by capillary sequencing. Finally, the expression of each fusion gene was determined by qRT-PCR using primer pairs spanning the breakpoint between genes. RNA-seq data is deposited and available at GEO (accession number GSE111263).

### SUPPLEMENTARY REFERENCES

1. Guiu J, Bergen DJ, De Pater E, et al. Identification of Cdca7 as a novel Notch transcriptional target involved in hematopoietic stem cell emergence. *J Exp Med*. 2014;211(12):2411-2423.

2. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009;25(14):1754-1760.

3. Zhang Y, Liu T, Meyer CA, et al. Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* 2008;9(9):R137.

4. Welch RP, Lee C, Imbriano PM, et al. ChIP-Enrich: gene set enrichment testing for ChIP-seq data. *Nucleic Acids Res.* 2014;42(13):e105.

5. Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. *Nat Methods*. 2013;10(11):1096-1098.

6. Picelli S, Faridani OR, Bjorklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. *Nat Protoc*. 2014;9(1):171-181.

7. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics*. 2015;31(2):166-169.

8. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 2014;15(12):550.

### SUPPLEMENTARY LEGENDS

**Figure S1. Coding sequence of the A4M fusion used in this study. (A)** The full-length cDNA was sequenced-verified. Fusion breakpoint is located in AF4 exon 2 and MLL exon 10. (**B**) Schematic of lentivectors used in this study.

**Figure S2.** Co-expression of MA4 and A4M promotes specification rather than survival/proliferation of HEPs. (A) Day 20 MA4-expressing hEBs display a significant higher HEP production coupled to an impaired blood (CD45+ and CD45+CD34+) formation. (B) *Left*, representative FACS analysis of the identification of HEPs and CD45<sup>+</sup> hematopoietic cells and their cell-cycle distribution. *Right*, frequency of proliferating (S+G<sub>2</sub>M phases) CD45+ blood cells and HEPs. (C) *Left*, representative FACS analysis of apoptotic CD45<sup>+</sup> hematopoietic cells and HEPs. *Right*, frequency of apoptotic (Annexin V+) HEPs and CD45+ hematopoietic cells for the indicated genotypes.

**Figure S3. H3K79me3 ChIP-seq profiles for the different genotypes.** (**A**) Correlation heatmap for both H3K79me3 and H3K4me3 using affinity scores based on read counts in consensus peaks distinguishes between the four experimental groups. (**B**) Venn diagrams depicting the number of differentially enriched genomic regions for H3K79me3 between experimental groups relative to EV. (**C**) Quantitative expression of the indicated *HOX-A* genes in CFUs from day 15 EV- and double-fusion-expressing HEPs.

**Figure S4. H3K4me2 profiles at genomic loci of MLL targets identified by Guenther** *et al.* Representative profiles for ChIP-seq using an anti-H3K4me<sup>3</sup> antibody at genomic sites of HOX-A (**A**) and non-HOX (**B**) MLL targets in the indicated genotypes of human ESC-differentiating derivatives.

## Α

AF4-MLL (8739 bp)

Red: AF4 exon 1-3

Blue: MLL exon 10 to 36


### ATG :Start Codon


### TAA :Stop Codon


ATC GCAGCCCAGTCAAGTTTGTACAATGACGACAGAAACCTGCTTCGAATTAGAGAGAAGGAA AGACGCAACCAGGAAGCCCACCAAGAGAAAGAGGCATTTCCTGAAAAGATTCCCCTTTTTGGA GAGCCCTACAAGACAGCAAAAGGTGATGAGCTGTCTAGTCGAATACAGAACATGTTGGGAAAC TACGAAGAAGTGAAGGAGTTCCTTAGTACTAAGTCTCACACTCATCGCCTGGATGCTTCTGAAA CCTTCCACACTAGTGTCCACCACCAGTCCATTCACACTCCTGCGTCTGGACCACTTTCTGTTGG CAACATTAGCCACAATCCAAAGATGGCGCAGCCAAGAACTGAACCAATGCCAAGTCTCCATGC CAAAAGCTGCGGCCCACCGGACAGCCAGCACCTGACCCAGGATCGCCTTGGTCAGGAGGGG TTCGGCTCTAGTCATCACAAGAAAGGTGACCGAAGAGCTGACGGAGACCACTGTGCTTCGGT GACAGATTCGGCTCCAGAGAGGGAGCTTTCTCCCTTAATCTCTTTGCCTTCCCCAGTTCCCCC TTTGTCACCTATACATTCCAACCAGCAAACTCTTCCCCGGACGCAAGGAAGCAGCAAGGTTCA TGGCAGCAGCAATAACAGTAAAGGCTATTGCCCAGCCAAATCTCCCAAGGACCTAGCAGTGAA AGTCCATGATAAAGAGACCCCTCAAGACAGTTTGGTGGCCCCTGCCCAGCCGCCTTCTCAGAC ATTTCCACCTCCCTCCCCTCCAAAAAGTGTTGCAATGCAGCAGAAGCCCACGGCTTATGT CCGGCCCATGGATGGTCAAGATCAGGCCCCTAGTGAATCCCCTGAACTGAAACCACTGCCGG CCAAACTGAAGATGCCTTCTCAGTCAGTTGAGGAGGATTGTGAAGCAGAAAATGTGTGGGAGA TGGGAGGCTTAGGAATCTTGACTTCTGTTCCTATAACACCCAGGGTGGTTTGCTTTCTCTGTGC CAGTAGTGGGCATGTAGAGTTTGTGTATTGCCAAGTCTGTTGTGAGCCCTTCCACAAGTTTTGT TTAGAGGAGAACGAGCGCCCTCTGGAGGACCAGCTGGAAAATTGGTGTTGTCGTCGTTGCAA ATTCTGTCACGTTTGTGGAAGGCAACATCAGGCTACAAAGCAGCTGCTGGAGTGTAATAAGTG CCGAAACAGCTATCACCCTGAGTGCCTGGGACCAAACTACCCCACCAAACCAAAGAAGAA GAAAGTCTGGATCTGTACCAAGTGTGTTCGCTGTAAGAGCTGTGGATCCACAACTCCAGGCAA AGGGTGGGATGCACAGTGGTCTCATGATTTCTCACTGTGTCATGATTGCGCCAAGCTCTTTGC TAAAGGAAACTTCTGCCCTCTCTGTGACAAATGTTATGATGATGATGACTATGAGAGTAAGATG ATGCAATGTGGAAAGTGTGATCGCTGGGTCCATTCCAAATGTGAGAATCTTTCAGGTACAGAA GATGAGATGTATGAGATTCTATCTAATCTGCCAGAAAGTGTGGCCTACACTTGTGTGAACTGTA CTGAGCGGCACCCTGCAGAGTGGCGACTGGCCCTTGAAAAAGAGCTGCAGATTTCTCTGAAG CAAGTTCTGACAGCTTTGTTGAATTCTCGGACTACCAGCCATTTGCTACGCTACCGGCAGGCT GCCAAGCCTCCAGACTTAAATCCCGAGACAGAGGAGAGTATACCTTCCCGCAGCTCCCCCGA AGGACCTGATCCACCAGTTCTTACTGAGGTCAGCAAACAGGATGATCAGCAGCCTTTAGATCT AGAAGGAGTCAAGAGGAAGATGGACCAAGGGAATTACACATCTGTGTTGGAGTTCAGTGATGA TATTGTGAAGATCATTCAAGCAGCCATTAATTCAGATGGAGGACAGCCAGAAATTAAAAAAGCC AACAGCATGGTCAAGTCCTTCTTCATTCGGCAAATGGAACGTGTTTTTCCATGGTTCAGTGTCA AAAAGTCCAGGTTTTGGGAGCCAAATAAAGTATCAAGCAACAGTGGGATGTTACCAAACGCAG TGCTTCCACCTTCACTTGACCATAATTATGCTCAGTGGCAGGAGCGAGAGGAAAACAGCCACA CTGAGCAGCCTCCTTTAATGAAGAAAATCATTCCAGCTCCCAAACCCAAAGGTCCTGGAGAAC CAGACTCACCAACTCCTCTGCATCCTCCTACACCACCAATTTTGAGTACTGATAGGAGTCGAGA AGACAGTCCAGAGCTGAACCCACCCCCAGGCATAGAAGACAATAGACAGTGTGCGTTATGTTT GACTTATGGTGATGACAGTGCTAATGATGCTGGTCGTTTACTATATTGGCCAAAATGAGTGG

ACACATGTAAATTGTGCTTTGTGGTCAGCGGAAGTGTTTGAAGATGATGACGGATCACTAAAGA ATGTGCATATGGCTGTGATCAGGGGGCAAGCAGCTGAGATGTGAATTCTGCCAAAAGCCAGGA GCCACCGTGGGTTGCTGTCTCACATCCTGCACCAGCAACTATCACTTCATGTGTTCCCGAGCC AAGAACTGTGTCTTTCTGGATGATAAAAAAGTATATTGCCAACGACATCGGGATTTGATCAAAG GCGAAGTGGTTCCTGAGAATGGATTTGAAGTTTTCAGAAGAGTGTTTGTGGACTTTGAAGGAAT CAGCTTGAGAAGGAAGTTTCTCAATGGCTTGGAACCAGAAAATATCCACATGATGATTGGGTCT ATGACAATCGACTGCTTAGGAATTCTAAATGATCTCCCGACTGTGAAGATAAGCTCTTTCCTAT TGGATATCAGTGTTCCAGGGTATACTGGAGCACCACAGATGCTCGCAAGCGCTGTGTATATAC ATGCAAGATAGTGGAGTGCCGTCCTCCAGTCGTAGAGCCGGATATCAACAGCACTGTTGAACA TGATGAAAACAGGACCATTGCCCATAGTCCAACATCTTTTACAGAAAGTTCATCAAAAGAGAGT GCTCCTGTTATTATCATGTCATCTCAAAGGTCCCCAGGATTCGAACACCCAGTTATTCTCCAAC ACAGAGATCCCCTGGCTGTCGACCGTTGCCTTCTGCAGGAAGTCCTACCCCAACCACTCATGA AATAGTCACAGTAGGTGATCCTTTACTCTCCTCTGGACTTCGAAGCATTGGCTCCAGGCGTCA CAGTACCTCTTCCTTATCACCCCAGCGGTCCAAACTCCGGATAATGTCTCCAATGAGAACTGG GAATACTTACTCTAGGAATAATGTTTCCTCAGTCTCCACCACCGGGACCGCTACTGATCTTGAA TCAAGTGCCAAAGTAGTTGATCATGTCTTAGGGCCACTGAATTCAAGTACTAGTTTAGGGCAAA ACACTTCCACCTCTTCAAATTTGCAAAGGACAGTGGTTACTGTAGGCAATAAAAACAGTCACTT GGATGGATCTTCATCTTCAGAAATGAAGCAGTCCAGTGCTTCAGACTTGGTGTCCAAGAGCTC CTCTTTAAAGGGAGAGAGACCAAAGTGCTGAGTTCCAAGAGCTCAGAGGGATCTGCACATAA TGTGGCTTACCCTGGAATTCCTAAACTGGCCCCACAGGTTCATAACACAACATCTAGAGAACTG AATGTTAGTAAAATCGGCTCCTTTGCTGAACCCTCTTCAGTGTCGTTTTCTTCTAAAGAGGCCC TCTCCTTCCCACACCTCCATTTGAGAGGGCAAAGGAATGATCGAGACCAACACACAGATTCTA CCCAATCAGCAAACTCCTCTCCAGATGAAGATACTGAAGTCAAAACCTTGAAGCTATCTGGAAT GAGCAACAGATCATCCATTATCAACGAACATATGGGATCTAGTTCCAGAGATAGGAGACAGAA AGGGAAAAAATCCTGTAAAGAAACTTTCAAAGAAAAGCATTCCAGTAAATCTTTTTGGAACCTG GTCAGGTGACAACTGGTGAGGAAGGAAACTTGAAGCCAGAGTTTATGGATGAGGTTTTGACTC CTGAGTATATGGGCCAACGACCATGTAACAATGTTTCTTCTGATAAGATTGGTGATAAAGGCCT TTCTATGCCAGGAGTCCCCAAAGCTCCACCCATGCAAGTAGAAGGATCTGCCAAGGAATTACA GGCACCACGGAAACGCACAGTCAAAGTGACACTGACACCTCTAAAAATGGAAAATGAGAGTCA ATCCAAAAATGCCCTGAAAGAAGTAGTCCTGCTTCCCCTTTGCAAATAGAGTCAACATCTCCC AATACCTCATGCCAGGATTCTCAAAGTAACAACTATCAGAATCTTCCAGTACAGGACAGAAACC TAATGCTTCCAGATGGCCCCCAAACCTCAGGAGGATGGCTCTTTTAAAAGGAGGTATCCCCGTC GCAGTGCCCGTGCACGTTCTAACATGTTTTTTGGGCTTACCCCACTCTATGGAGTAAGATCCTA TGGTGAAGAAGACATTCCATTCTACAGCAGCTCAACTGGGAAGAAGCGAGGCAAGAGATCAGC TGAAGGACAGGTGGATGGGGCCGATGACTTAAGCACTTCAGATGAAGACGACTTATACTATTA CGGGAGGAGGAACAGTGTGATCTTCCAAAAATCTCACAGTTGGATGGTGTTGATGATGGGACA GAGAGTGATACTAGTGTCACAGCCACAACAAGGAAAAGCAGCCAGATTCCAAAAAGAAATGGT GTCACTAAGAGTTCTGTTGGCCACAAAAATGAGCCAAAGATGGATAACTGCCATTCTGTAAGCA GAGTTAAAACACAGGGACAAGATTCCTTGGAAGCTCAGCTCAGCTCATTGGAGTCAAGCCGCA GAGTCCACACAAGTACCCCCTCCGACAAAAATTTACTGGACACCTATAATACTGAGCTCCTGAA ATCAGATTCAGACAATAACAACAGTGATGACTGTGGGGAATATCCTGCCTTCAGACATTATGGAC TTTGTACTAAAGAATACTCCATCCATGCAGGCCTTTGGGTGAGAGCCCAGAGTCATCTTCATCAG AACTCCTGAATCTTGGTGAAGGATTGGGTCTTGACAGTAATCGTGAAAAAGACATGGGTCTTTT TGAAGTATTTTCTCAGCAGCTGCCTACAACAGAACCTGTGGATAGTAGTGTCTCTTCCTCTATC TCAGCAGAGGAACAGTTTGAGTTGCCTCTAGAGCTACCATCTGATCTGTCTTGACCACC CGGAGTCCCACTGTCCCCAGCCAGAATCCCAGTAGACTAGCTGTTATCTCAGACTCAGGGGA GAAGAGAGTAACCATCACAGAAAAATCTGTAGCCTCCTCTGAAAGTGACCCAGCACTGCTGAG CCCAGGAGTAGATCCAACTCCTGAAGGCCACATGACTCCTGATCATTTTATCCAAGGACACAT


GGATGCAGACCACATCTCTAGCCCTCCTTGTGGTTCAGTAGAGCAAGGTCATGGCAACAATCA GGATTTAACTAGGAACAGTAGCACCCCTGGCCTTCAGGTACCTGTTTCCCCAACTGTTCCCAT CCAGAACCAGAAGTATGTGCCCAATTCTACTGATAGTCCTGGCCCGTCTCAGATTTCCAATGCA GCTGTCCAGACCACTCCACCCCACCTGAAGCCAGCCACTGAGAAACTCATAGTTGTTAACCAG AACATGCAGCCACTTTATGTTCTCCAAACTCTTCCAAATGGAGTGACCCAAAAAATCCAATTGA CCTCTTCTGTTAGTTCTACACCCAGTGTGATGGAGACAAATACTTCAGTATTGGGACCCATGGG AGGTGGTCTCACCCTTACCACAGGACTAAATCCAAGCTTGCCAACTTCTCAATCTTTGTTCCCT CTCAAAGTAGTTTCCCACCAAACATCAGCAATCCTCCTTCAGGCCTGCTTATTGGGGTTCAGCC AGCCACTCCATCCTCTGGACTCAAGAAAAGACCCATATCTCGTCTACAGACCCGAAAGAATAAA AAACTTGCTCCCTCTAGTACCCCTTCAAACATTGCCCCCTTCTGATGTGGTTTCTAATATGACATT GATTAACTTCACACCCTCCCAGCTTCCTAATCATCCAAGTCTGTTAGATTTGGGGTCACTTAATA CTTCATCTCACCGAACTGTCCCCCAACATCATAAAAAGATCTAAATCTAGCATCATGTATTTTGAA AATAAGCCAGGATACTAGCCACCTCACATCAGGGTCTGTGTCTGGCTTGGCATCCAGTTCCTC TGTCTTGAATGTTGTATCCATGCAAACTACCACAACCCCTACAAGTAGTGCGTCAGTTCCAGGA CACGTCACCTTAACCAACCCAAGGTTGCTTGGTACCCCAGATATTGGCTCAATAAGCAATCTTT TAATCAAAGCTAGCCAGCAGAGCCTGGGGATTCAGGACCAGCCTGTGGCTTTACCGCCAAGTT CAGGAATGTTTCCACAACTGGGGGACATCACAGACCCCCTCTACTGCTGCAATAACAGCGGCAT CTAGCATCTGTGTGCTCCCCTCCACTCAGACTACGGGCATAACAGCCGCTTCACCTTCTGGGG AAGCAGACGAACACTATCAGCTTCAGCATGTGAACCAGCTCCTTGCCAGCAAAACTGGGATTC ATTCTTCCCAGCGTGATCTTGATTCTGCTTCAGGGCCCCAGGTATCCAACTTTACCCAGACGGT AGACGCTCCTAATAGCATGGGACTGGAGCAGAACAAGGCTTTATCCTCAGCTGTGCAAGCCAG CCCCACCTCTCCGGGGGTTCTCCATCTCTCCATCTTCTGGACAGCGGTCAGCAAGCCCTTC AGTGCCGGGTCCCACTAAACCCAAACCAAAACCAAACGGTTTCAGCTGCCTCTAGACAAAGG GAATGGCAAGAAGCACAATGTTTCCCATTTGCGGACCAGTTCTTCTGAAGCACACATTCCAGA CCAAGAAACGACATCCCTGACCTCAGGCACAGGGACTCCAGGAGCAGAGGCTGAGCAGCAG GATACAGCTAGCGTGGAGCAGTCCTCCCAGAAGGAGTGTGGGCAACCTGCAGGGCAAGTCGC TGTTCTTCCGGAAGTTCAGGTGACCCAAAATCCAGCAAATGAACAAGAAAGTGCAGAACCTAA AACAGTGGAAGAAGAGGAAAGTAATTTCAGCTCCCCACTGATGCTTTGGCTTCAGCAAGAACA AAAGCGGAAGGAAAGCATTACTGAGAAAAAACCCCAAGAAAGGACTTGTTTTTGAAATTTCCAGT GATGATGGCTTTCAGATCTGTGCAGAAAGTATTGAAGATGCCTGGAAGTCATTGACAGATAAAG TCCAGGAAGCTCGATCAAATGCCCGCCTAAAGCAGCTCTCATTTGCAGGTGTTAACGGTTTGA GGATGCTGGGGGATTCTCCATGATGCAGTTGTGTTCCTCATTGAGCAGCTGTCTGGTGCCAAGC ACTGTCGAAATTACAAATTCCGTTTCCACAAGCCAGAGGAGGCCAATGAACCCCCCTTGAACC CTCACGGCTCAGCCAGGGCTGAAGTCCACCTCAGGAAGTCAGCATTTGACATGTTTAACTTCC TGGCTTCTAAACATCGTCAGCCTCCTGAATACAACCCCCAATGATGAAGAAGAGGAGGAGGAGGTAC AGCTGAAGTCAGCTCGGAGGGCAACTAGCATGGATCTGCCAATGCCCATGCGCTTCCGGCAC TTCTGTAAGAGAAACATTGATGCAGGTGAGATGGTGATTGAGTATGCCGGCAACGTCATCCGC TCCATCCAGACTGACAAGCGGGAAAAGTATTACGACAGCAAGGGCATTGGTTGCTATATGTTC CACTCGTGTGAGCCTAACTGCTATTCTCGGGTCATCAATATTGATGGGCAGAAGCACATTGTCA TCTTTGCCATGCGTAAGATCTACCGAGGAGGAGGAACTCACTTACGACTATAAGTTCCCCATTGA GGATGCCAGCAACAAGCTGCCCTGCAACTGTGGCGCTAAGAAATGCCGGAAGTTCCTAAACTA









В



С

CFU





### H3K4me3 HOXA cluster

Α

